EGFR and non-small cell lung carcinoma: Of the 390 EGFRm NSCLC patients enrolled into the CEE cohort, one was not eligible for inclusion in the analysis due to 1L EGFR TKI therapy start outside the study period, leaving 389 medical records reviewed across the CEE countries and distributed as follows: 31% (120/389) in Slovenia, 28% (110/389) in Poland, 23% (90/389) in Romania, and 18% (69/389) in Bulgaria.